Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz’ Symjepi Set To Undercut Rivals

Executive Summary

Sandoz has set a US launch price for its Symjepi epinephrine anaphylaxis treatment that is significantly below that of Mylan’s EpiPen and Teva’s generic.

You may also be interested in...



Asia Deal Watch: Daiichi Sankyo Acquires Partial Asian Rights To Three Astellas Drugs

Daiichi Sankyo obtains rights to antiemetic Nasea and the anti-hypertension drugs Perdipine and Oldeca. Mitsubishi Tanabe licenses Asian rights to Viela’s inebilizumab for a rare eye disorder.

Sandoz Seeks Help From Doctors For US Symjepi Push

Sandoz is encouraging US doctors to write prescriptions for epinephrine that include its Symjepi pre-filled syringes, and not just for auto-injector devices, as it targets the retail sector.

Sandoz Phases US Epinephrine Entry

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB001561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel